title: Use of  half-dose gadolinium-enhanced MRI and magnetization transfer saturation in brain tumors.
abstract: The aim of this study was to search if half-dose gadolinium (Gd)-enhanced MR imaging with magnetization transfer saturation (MT) can replace standard-dose T1-weighted spin echo (SE) without MT saturation in brain tumors. Thirty patients with a total of 33 brain tumors (14 gliomas, 13 meningiomas, 6 metastases) were prospectively studied using T1-weighted SE half-dose of Gd with MT, and T1-weighted SE standard-dose Gd without MT. The contrast-to-noise ratio (CNR) of the two sequences was calculated and four radiologists reviewed qualitatively the images of the two sequences. There was no significant difference between both techniques for quantitative analysis (Wilcoxon test). However, there was a good agreement between sequences to evidence an intraclass correlation coefficient (r = 0.70) of all lesions. In cases of meningioma, the agreement was better (r = 0.84). The results show a difference in the qualitative data between the two sequences, suggesting the use of the T1-weighted MR images with MT and half-dose of Gd with good results in the whole tested parameters except the lesional edema and the presence of artifacts. Half-dose T1-weighted SE with MT can replace standard-dose T1-weighted SE without MT with no loss of contrast enhancement in investigation of meningiomas and saving 50% of the contrast material.
authors.affiliation: Department of Radiology, University Hospital of Angers, France.
authors.forename: D
authors.initials: D
authors.lastname: Haba
authors.forename: A
authors.initials: A
authors.lastname: Pasco Papon
authors.forename: J Y
authors.initials: JY
authors.lastname: Tanguy
authors.forename: P
authors.initials: P
authors.lastname: Burtin
authors.forename: C
authors.initials: C
authors.lastname: Aube
authors.forename: C
authors.initials: C
authors.lastname: Caron-Poitreau
mesh_terms: D000328:Adult; D000368:Aged; D001921:Brain / Q000473:pathology; D001929:Brain Edema / Q000175:diagnosis; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000556:secondary; D003287:Contrast Media / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005910:Glioma / Q000175:diagnosis*; D006801:Humans; D007089:Image Enhancement; D008279:Magnetic Resonance Imaging; D008297:Male; D008536:Meglumine; D008577:Meningeal Neoplasms / Q000175:diagnosis*; D008579:Meningioma / Q000175:diagnosis*; D008875:Middle Aged; D009942:Organometallic Compounds; D012680:Sensitivity and Specificity
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; D008536:Meglumine; C072417:gadoterate meglumine